120100-15-4

Basic information

• Product Name: Methyl 3-aMino-2-chlorobenzoate
• Synonyms: Methyl 3-aMino-2-chlorobenzoate
• CAS NO: 120100-15-4
• Molecular Formula: C₈H₈ClNO₂
• Molecular Weight: 185.60762
• Mol File: 120100-15-4.mol

Chemical Properties

• Boiling Point: 298.5±20.0 °C(Predicted)
• Appearance: /
• Density: 1.311±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.51±0.10(Predicted)
• CAS DataBase Reference: Methyl 3-aMino-2-chlorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-aMino-2-chlorobenzoate(120100-15-4)
• EPA Substance Registry System: Methyl 3-aMino-2-chlorobenzoate(120100-15-4)

Safety Data

• Hazardous Substances Data: 120100-15-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 3-amino-2-chlorobenzoate is utilized as a key building block in the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 3-amino-2-chlorobenzoate serves as an essential component in the production of pesticides and other crop protection agents. Its incorporation enhances the effectiveness of these products in managing pests and diseases.
Used in Organic Synthesis:
Methyl 3-amino-2-chlorobenzoate is employed as a versatile intermediate in organic synthesis for the preparation of a wide range of organic compounds. Its reactivity and functional groups make it a valuable precursor for the creation of various chemical entities.

Upstream product

• 53553-14-3 2-chloro-3-nitrobenzoic acid methyl ester 
• 3970-35-2 2-chloro-3-nitrobezoic acid 
• 67-56-1 methanol 
• 108679-71-6 2-chloro-3-aminobenzoic acid 

Downstream Products

• 247903-17-9 3-(3-carbomethoxy-2-chloroanilino)cyclohex-2-en-1-one 
• 1195768-68-3 methyl 2-chloro-3-{[(2-propen-1-yloxy)carbonyl]amino}benzoate 
• 1195768-58-1 C₁₄H₁₀ClF₂NO₄S 
• 528607-66-1 methyl 2-chloro-3-(3-cyano-4-isobutyloxybenzoylamino)benzoate 
• 1353575-44-6 methyl 2-chloro-3-pivalamidobenzoate 
• 1307272-36-1 N-(2-chloro-3-(2-(2-chloropyrimidin-4-yl)acetyl)phenyl)propane-1-sulfonamide 
• 1307272-07-6 N-(3-(2-bromo-2-(2-chloropyrimidin-4-yl)acetyl)-2-chlorophenyl)propane-1-sulfonamide 
• 1307272-32-7 N-{2-chloro-3-[(2-chloro-4-pyrimidinyl)acetyl]phenyl}-3,3,3-trifluoro-1-propanesulfonamide 
• 1307272-64-5 N-(2-chloro-3-(5-(2-chloropyrimidin-4-yl)-2-(1-hydroxy-2-methylpropan-2-yl)thiazol-4-yl)phenyl)propane-1-sulfonamide 
• 1307272-41-8 N-{2-chloro-3-[5-(2-chloro-4-pyrimidinyl)-2-(tetrahydro-2H-pyran-4-yl)-1,3-thiazol-4-yl]phenyl}-1-propanesulfonamide 
• 1307271-14-2 N-{2-chloro-3-[5-{2-[(2-hydroxy-2-methylpropyl)amino]-4-pyrimidinyl}-2-(tetrahydro-2H-pyran-4-yl)-1,3-thiazol-4-yl]phenyl}-1-propanesulfonamide 
• 1307296-89-4 N-{2-chloro-3-[5-{2-[(2-hydroxyethyl)amino]-4-pyrimidinyl}-2-(tetrahydro-2H-pyran-4-yl)-1,3-thiazol-4-yl]phenyl}-1-propanesulfonamide 
• 1307272-73-6 1,1-dimethylethyl 4-[4-{2-chloro-3-[(propylsulfonyl)amino]phenyl}-5-(2-chloro-4-pyrimidinyl)-1,3-thiazol-2-yl]-1-piperidinecarboxylate 
• 1307272-74-7 1,1-dimethylethyl 4-(5-(2-amino-4-pyrimidinyl)-4-{2-chloro-3-[(propylsulfonyl)amino]phenyl}-1,3-thiazol-2-yl)-1-piperidinecarboxylate 

Relevant articles and documents

From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4)

The mitogen-activated protein kinase (MAP) kinase 4 (MKK4) was found to be a major regulator of liver regeneration and could be a valuable drug target addressing liver related diseases by restoring its intrinsic regenerative capacity. We report on the synthesis and optimization of novel MKK4 inhibitors following a target-hopping strategy from the FDA-approved BRAFV600E inhibitor PLX4032 (8). Applying an iterative multi-parameter optimization process we carved out essential structural features yielding in compounds with a low nanomolar affinity for MKK4 and excellent selectivity profiles against the main off-targets MKK7 and JNK1, which, upon relevant inhibition, would totally abrogate the pro-regenerative effect of MKK4 inhibition, as well as against the off-targets MAP4K5, ZAK and BRAF with selectivity factors ranging from 40 to 430 for our best-balanced compounds 70 and 73.

TRANSGLUTAMINASE 2 (TG2) INHIBITORS

Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.

COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH

The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.

The second factor as inhibitor XIA pyridonecarboxylic dihydropyridines P1

The present invention provides compounds of Formula (X):(Formula (X), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir 1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.

BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

Benzene Sulfonamide Thiazole and Oxazole Compounds

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

Palladium-catalyzed indole and azaindole synthesis by direct annulation of electron-poor o-chloroanilines and o-chloroaminopyridines with aldehydes

A practical process for the synthesis of 2-unsubstituted indoles and azaindoles has been developed by the palladium-catalyzed direct annulation of electron-poor o-chloro/bromoanilines and o-chloroaminopyridines with aldehydes. Coupled with the previous results of Jia and Zhu, this allows rapid access to a variety of 2-unsubstituted indoles and azaindoles starting from simple and easily accessible precursors. Georg Thieme Verlag Stuttgart.